Transforming medicine

Generics Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

Interim Results for the Six Months ended 30 June 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

Generics Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

Annual General Meeting Results and Statement

Generics’s BARHEMSYS® Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients

Notice of Annual General Meeting

Generics Receives Complete Response Letter from FDA for BARHEMSYS®

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

Results for the year ended 31 December 2018

Editorial in Anesthesiology on Positive Data for BARHEMSYS™ PONV Rescue Treatment

Supportive Cardiac Safety Data for BARHEMSYS™